Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers

SAN FRANCISCO--(BUSINESS WIRE)--Mar 26, 2026--

Hims & Hers Health, Inc. (NYSE: HIMS) today announced that a broad assortment of Novo Nordisk’s FDA-approved GLP-1 medications are available to eligible customers, including the Wegovy® pill, which is the only FDA-approved GLP-1 weight loss pill. 1 As a part of a collaboration with Novo Nordisk, Hims & Hers is making it simpler for customers to access FDA-approved GLP-1 medications which are now available at more affordable prices, with more doses and delivery methods. This expansion makes Hims & Hers the largest global consumer health platform for affordable access to approved medications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326503294/en/

Based on an independent provider’s clinical decision, eligible Hims & Hers customers can now access Novo Nordisk treatments that can help them lose up to 20% of their body weight. 2 Medication options include Wegovy® (semaglutide) 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg injection and 1.5 mg, 4 mg, 9 mg, and 25 mg pills, with Wegovy® (semaglutide) 7.2 mg injection coming soon. Ozempic® (semaglutide) 0.25 mg, 0.5 mg, 1 mg, and 2 mg injection pens, which are approved as treatments for Type 2 diabetes, will also be available for eligible patients based on individual clinical judgment. Ozempic is not FDA-approved for weight loss. Prices start as low as $149 a month. 3

“Today we’re taking an important next step toward building a better model of healthcare that works for everyday people,” said Andrew Dudum, co-founder and CEO of Hims & Hers. “When healthcare innovators work together, we can make sure customer access moves at the same speed as innovation. As the largest global consumer health platform, we’re thrilled to be working alongside Novo Nordisk to help more people feel their best and we’re excited to find more ways to collaborate across the industry.”

“Obesity medications have evolved over the last several years to become more affordable, more flexible, and more approachable for every kind of patient,” said Dr. Craig Primack, SVP Weight Management at Hims & Hers. “As a part of our comprehensive treatment program, these FDA-approved medications will help more people get and stay healthy. We’re excited to see how our customers succeed as more innovative treatments become available.”

The company is also introducing a new membership for weight loss, which will include comprehensive support services, 24/7 direct access to providers, personalized nutrition guidance, ongoing clinical check-ins, as well as peer support in the Hers Weight Loss community. Membership starts at $39 for the first month, $149 each month after. 4 Medication costs are separate and may be covered under the customer’s HSA and FSA plan. All Hims & Hers subscribers have access to special savings.

Customers will be educated on this expanding assortment of FDA-approved medications, and if determined clinically appropriate by their providers, will be given the opportunity to transition seamlessly to those medications. For what is anticipated to be a limited set of customers whose clinical needs cannot be met using the increasingly varied set of commercially available FDA-approved GLP-1s, Hims & Hers plans to offer access to compounded GLP-1s if a provider determines that a compounded product is clinically necessary.

For more information, visit www.hims.com/weight-loss or www.forhers.com/weight-loss.

About Hims & Hers Health, Inc

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

Disclaimers

This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “anticipates,” “expects,” “intends,” “plans,” “decides,” “may,” “will,” “likely,” “potential,” “future,” “coming,” “hope,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding the offerings and services accessible on our platform, including their diversity, efficacy, pricing, dosages, and timing of availability; the quotes from our CEO and SVP, Weight Management; statements regarding the education of our customers on a broad assortment of FDA-approved medications and the potential transition to such medications; statements regarding our plans to offer access to compounded GLP-1s if a provider determines that a compounded product is clinically necessary and the expectation that such customer set will be limited; statements regarding future collaborations or expanded access to treatment options; and statements regarding the membership model, including pricing thereof and what it is expected to include. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the timing and logistical considerations related to updating access to the semaglutide offerings available on our platform (branded and compounded), and the related customer response; the timing or feasibility of potential future partnerships or collaborations or expanded access to treatment options available on our platform; risks related to our international expansion efforts, including any pending or completed acquisitions, and the timing, integration and performance thereof; changes in the application, interpretation, and enforcement of healthcare, consumer protection or privacy laws or regulations applicable to our business; the timing, outcome or impact of this announcement on ongoing litigation, governmental actions or regulatory statements; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission. In addition, at this time we cannot predict or estimate the impact any collaboration with Novo Nordisk and / or the impact any shift in our GLP-1 business may have on our future results, including revenue or EBITDA.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of March 26, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.

1 Not available in all 50 states. Prescription required. Weight Loss by Hims & Hers is a holistic program that includes nutrition support, technological tools, and medications prescribed based on what your provider determines is medically appropriate and necessary for you. See website for full details, important safety information, and restrictions. Wegovy® is a registered trademark of Novo Nordisk A/S.
2 In separate clinical studies of adults with overweight or obesity, about 1 in 4 taking Wegovy® oral semaglutide 25 mg (64 weeks), about 1 in 3 taking Wegovy® injection 2.4 mg (68 weeks), and about 1 in 2 taking Wegovy® injection 7.2 mg (72 weeks) lost ≥20% of body weight, alongside diet and exercise. Average weight loss was approximately 14–19%. Individual results may vary. Stopping treatment may result in weight regain.
3 Membership required, fee not included, and billed separately.
4 Price includes membership fee only. Membership is billed separately and does not include or guarantee a prescription. Medication is not available without a membership.

Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight loss pill.

Former Venezuelan President Nicolás Maduro returns to a New York courtroom Thursday as he seeks to have his drug trafficking indictment thrown out over a geopolitical dispute over legal fees.

It’s the first time that Maduro and his wife, Cilia Flores, will be in court since a January arraignment at which he protested their capture by U.S. military forces and declared: “I am not guilty. I am a decent man, the constitutional president of my country.” Flores has also pleaded not guilty.

Both remain jailed at a detention center in Brooklyn, and neither has asked to be released on bail. Judge Alvin Hellerstein has yet to set a trial date, though that could happen at the hearing.

Here is the latest:

Maduro’s attorney is arguing that if the former Venezuelan president gets public defenders, that would sap legal resources that are meant for people who can’t afford their own attorneys.

Pollack is telling the judge that doesn’t make sense in “a case where you have someone other than the U.S. taxpayer standing ready, willing and able to fund that defense.”

Maduro lawyer Barry Pollack is making complex legal arguments for why the U.S. should let Maduro access Venezuelan government funds to pay for his defense.

The judge is asking questions.

Maduro appears to be taking notes.

Maduro, in a jail uniform, is seated between his attorneys at a defense table.

He glanced at his wife, who is sitting between her own attorneys to the right of him and his attorneys. She’s also in a jail uniform.

The couple are both wearing headphones to hear interpretation.

Former Venezuelan President Nicolás Maduro has been brought into a New York courtroom as he seeks to have his drug trafficking indictment thrown out over a geopolitical dispute over legal fees.

Thursday’s hearing is the first time Maduro and his wife, Cilia Flores, have been in court since a January arraignment at which he protested their capture by U.S. military forces and declared: “I am not guilty. I am a decent man, the constitutional president of my country.” Flores has also pleaded not guilty.

Judge Alvin Hellerstein has yet to set a trial date, though that could happen at Thursday’s hearing.

In Caracas, Eduardo Cubillan condemned the violation of Venezuela’s sovereignty during the Jan. 3 operation. But the 80-year-old retiree hesitated to say whether he would like Maduro to return as president.

While Maduro’s ruling party remains in power, he has slowly been erased from the government of Delcy Rodríguez, Venezuela’s acting president. Cubillan’s hesitation reflected a dilemma that many ruling party supporters face as they see Rodríguez reach agreements with the U.S. that could bring economic improvements.

“We hope that in the United States, if justice truly exists, a trial will be held that will lead to President Maduro’s freedom, because this kidnapping violated international legal principles, and we want justice to be served,” Cubillan said.

During his Cabinet meeting, President Trump accused Maduro of being a “major purveyor of drugs coming into our country.”

Trump said Maduro would be given “a fair trial. But I would imagine there are other trials coming.” He didn’t provide details, but suggested the current charges Maduro is facing might be “a fraction of the kind of things that he’s done.”

Protesters and supporters are still gathering. They’re chanting, blowing horns and beating drums and cowbells.

Among the anti-Maduro contingent, one person is waving a sign reading, “Maduro rot in prison.”

On the other side of a metal barrier, people wave signs saying, “Free President Maduro.”

The officer prefaced Thursday’s hearing with a warning to spectators to stay quiet and seated while the former Venezuelan president is in the courtroom.

People who speak out will be removed and could face legal consequences, he said. The officer acknowledged, “This may be a sensitive case for some of you” and added, “you’re in a federal courthouse. Please respect the institution and what it stands for.”

In Caracas, many attendees wore the uniform of their state agency employer, took selfies to report to managers their participation at the event and waved Venezuelan flags as a group played regional music.

A woman attached action figures modeled after Maduro and Flores to her flag.

A screen behind the stage showed a photo of the couple taken during Maduro’s January 2025 swearing in ceremony and the phrase “83 days have gone by since their kidnapping.”

In Venezuela’s capital, a couple hundred people, among them ruling party supporters, state employees and civilian militia members, gathered at a public plaza Thursday morning, planning to pray for Maduro and Flores and to watch the couple’s hearing, unaware that U.S. federal courts do not allow cameras.

A large screen mixed footage of Maduro, the Venezuelan flag and the country’s recent World Baseball Classic championship win.

“We are going to see him today,” ruling party leader Carmen Melendez told the crowd. “We may see him skinnier. … But that’s our president.”

A group of demonstrators held Venezuela flags and signs saying “Free President Maduro.” They also shouted “No boots on the ground, no bombs in the air. U.S. out of everywhere,” denouncing U.S. military actions abroad.

Some carried an inflatable doll depicting Maduro in orange clothing resembling prison garb.

Signs indicated some of the protesters were affiliated with the Workers World Party, which describes itself as a revolutionary socialist party.

The last time Maduro appeared at the courthouse, he was brought there in spectacular fashion.

A helicopter flew him from Brooklyn to a heliport in Manhattan, where a motorcade of law enforcement vehicles whisked him to the courthouse in just a few minutes.

The city’s multiple local and federal law enforcement agencies have made an art form out of transporting important people through streets that are often choked with traffic.

When Trump was on trial at a courthouse in the same Lower Manhattan neighborhood in 2024, police made sure his Secret Service motorcade also had an unobstructed and traffic-free path to the courthouse.

The judge presiding over Maduro’s case is 92 years old.

A native New Yorker, Alvin K. Hellerstein was nominated to the court by President Bill Clinton in 1998.

He’s not the oldest judge on the federal bench in New York. That honor belongs to Judge Louis L. Stanton, who is 98.

Hellerstein has handled many other big cases. For nearly 25 years, he has also presided over civil litigation resulting from the Sept. 11 terrorist attacks on New York.

Legal issues surrounding the drug trafficking case against Maduro are expected to be complex, but they are unlikely to surface in a prolonged way at Thursday’s hearing.

The main subject of the court appearance involves how to pay his lawyers. Because of U.S. sanctions, the legal team can’t simply accept a check from Venezuela’s government. They need permission from the U.S. government. But U.S. authorities don’t want to grant it. They say Maduro can pay for his defense himself.

The dispute will get worked out in court.

Seating will be limited inside the courtroom where Maduro was to appear, and the line to get in started forming a day early.

Several professional line sitters in tiny tents were set up outside the court by Wednesday afternoon.

Some news organizations spent hundreds of dollars to pay people to hold spots for reporters who would arrive in the morning when the courthouse opened.

The indictment against Maduro accuses him of carrying out a wide-ranging conspiracy to traffic illegal drugs into the U.S. for more than a quarter century.

It says he cleared the way for thousands of tons of cocaine to enter the United States by teaming up at times with Venezuelan law enforcement to aid drug kingpins.

Maduro says he’s innocent. His supporters say that the U.S. military seized Maduro because U.S. President Donald Trump wanted regime change in Venezuela.

Demonstrators protest outside Manhattan federal court before a pre-trial hearing in former Venezuela President Nicolas Maduro's drug trafficking case, Thursday, March 26, 2026, in New York. (AP Photo/Heather Khalifa)